November 13, 2018
Securing the clinical supply chain comes down to the notion of ‘compliance’, which is transitioning from a ‘nice to have’ to a ‘need to have,’ says Mark W. Sawicki, Ph.D., Chief Commercial officer of...
November 06, 2018
Regenerative medicine advanced therapies in the form of cell and gene therapies are breaking new ground, providing patients the potential of treatment, reversal or even cure of serious and...
August 20, 2018
The emergence of regenerative medicine as a viable therapy class has created an urgency to review and improve upon the current quality systems distribution standards that are employed in support of...
June 14, 2018
Chain of Compliance® is vital for the Regenerative Medicine Advanced Therapy (RMAT) market which presents a major opportunity for the industry. In a recent Contract Pharma article, Mark W. Sawicki,...
Americas • EMEA • APAC
Sales • +1 949.470.2300 | Support • +1 949.470.2305
©2023 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC
